288 related articles for article (PubMed ID: 11558856)
1. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
3. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
Manolis AJ; Grossman E; Jelakovic B; Jacovides A; Bernhardi DC; Cabrera WJ; Watanabe LA; Barragan J; Matadamas N; Mendiola A; Woo KS; Zhu JR; Mejia AD; Bunt T; Dumortier T; Smith RD
Clin Ther; 2000 Oct; 22(10):1186-203. PubMed ID: 11110230
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
Townsend R; Haggert B; Liss C; Edelman JM
Clin Ther; 1995; 17(5):911-23. PubMed ID: 8595643
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension.
Roca-Cusachs A; Oigman W; Lepe L; Cifkova R; Karpov YA; Harron DW
Acta Cardiol; 1997; 52(6):495-506. PubMed ID: 9542575
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J
Clin Ther; 1996; 18(4):608-25. PubMed ID: 8879890
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
9. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators.
Monterroso VH; Rodriguez Chavez V; Carbajal ET; Vogel DR; Aroca Martinez GJ; Garcia LH; Cuevas JH; Lara Teran J; Hitzenberger G; Leao Neves P; Middlemost SJ; Dumortier T; Bunt AM; Smith RD
Adv Ther; 2000; 17(2):117-31. PubMed ID: 11010055
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
14. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.
Watanabe LA; Wei M; Sun N; Kim D; Chiang CE; Ke Y; Tseng CD; Coloma R; Vala M; Massaad R; Feig P; Guptha S
Curr Med Res Opin; 2006 Oct; 22(10):1955-64. PubMed ID: 17022855
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
Hong SJ; Ahn TH; Baek SH; Cho WH; Jeon HK; Kwan J; Yoon MH; Lee KJ; Lim DS
Clin Ther; 2006 Apr; 28(4):537-51. PubMed ID: 16750465
[TBL] [Abstract][Full Text] [Related]
16. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
18. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
